Business And Finance, In Brief
Executive Summary
Sanofi Collaborates With UCSF
You may also be interested in...
Deals Of The Week: Merck/Parexel, Biotie/Synosia, Bristol-Myers Squibb/Pharmasset
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
Deals Of The Week: Merck/Parexel, Biotie/Synosia, Bristol-Myers Squibb/Pharmasset
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
As Pfizer And UCSF Tighten Ties, More Deals With Academia Could Follow
Pfizer Inc.’s latest pledge to academic research, a five-year $85 million agreement to fund projects at the University of California, San Francisco, isn’t just a deepening of the Big Pharma’s commitment to on-campus studies intended to bridge the so-called Valley of Death between the laboratory and the commercial sector. It’s also a sign of the increased importance of deals between pharmas and universities, which give commercial partners access to new research earlier in the development process while nudging academics toward projects with commercial relevance in mind.